A carregar...
Resistant mutations in CML and Ph(+)ALL – role of ponatinib
In 2012, ponatinib (Iclusig(®)), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4208348/ https://ncbi.nlm.nih.gov/pubmed/25349473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S50734 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|